480423-17-4Relevant articles and documents
Development of Potent PfCLK3 Inhibitors Based on TCMDC-135051 as a New Class of Antimalarials
Mahindra, Amit,Janha, Omar,Mapesa, Kopano,Sanchez-Azqueta, Ana,Alam, Mahmood M.,Amambua-Ngwa, Alfred,Nwakanma, Davis C.,Tobin, Andrew B.,Jamieson, Andrew G.
supporting information, p. 9300 - 9315 (2020/10/19)
The protein kinase PfCLK3 plays a critical role in the regulation of malarial parasite RNA splicing and is essential for the survival of blood stage Plasmodium falciparum. We recently validated PfCLK3 as a drug target in malaria that offers prophylactic,
General methods for the synthesis and late-stage diversification of 2,4-substituted 7-azaindoles
Varnes, Jeffrey G.,McGuire, Thomas,Meadows, Rebecca E.,Barlaam, Bernard,Clark, Jemma,Cook, Calum R.,Davison, Gemma,Dishington, Allan,De Savi, Chris,Donald, Craig,Grebe, Tyler,Hande, Sudhir,Hawkins, Janet,Hird, Alexander W.,Holmes, Jane,Lister, Andrew,Lucas, Simon,Moore, Jane,Moore, Esther,Patel, Anil,Pike, Kurt G.,Roberts, Bryan,Stark, Andrew,Stead, Darren,Thakur, Kumar,Turner, Paul,Vasbinder, Melissa,Yang, Bin
supporting information, p. 4718 - 4722 (2016/09/28)
As part of a medicinal chemistry program, we adapted known synthetic methods for the late-stage diversification of 2,4-substituted 7-azaindoles. The strengths and weaknesses of these strategies are discussed. In the course of this work, three optimized co
PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS
-
Page/Page column 455, (2014/09/29)
Disclosed are compounds of Formula (IIa), wherein R1, R2, R3A, R3B, R3C, R3D, R3E, and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIa)